Studies using IL-21R antagonists in humanized mouse skin graft models found a significant reduction in the proportion of pSTAT3-positive CD4+ T cells, fewer infiltrating CD4+, CD8+, and CD20+ cells in grafts, and significantly lower levels of skin inflammation markers such as Ker17 and Ki-67 (115). Here, CD4 is linked to neoplasm.